Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
In this small group of individuals with MDR HIV who were heavily treatment-experienced and/or faced adherence challenges, the use of IBA + LEN ± OBR was well tolerated and led to clinically significant reductions in viral loads and improvements in CD4+ counts.
Authors
- Claudia Martorell
- Tammie McClendon
- Christopher Harbison
- Diana Finkel (ORCID: https://orcid.org/0000-0002-5947-9947)
- Jihad Slim (ORCID: https://orcid.org/0000-0002-4192-7246)
- Christopher Lucasti (ORCID: https://orcid.org/0000-0001-8720-7677)
- Amit C. Achhra (ORCID: https://orcid.org/0009-0002-8954-345X)
- Charlotte Rolle
Institutions
- Rutgers, The State University of New Jersey (US)
- New York Medical College (US)
- Wayne State University (US)
- Shore Memorial Hospital (US)
- Yale University (US)
- VA North Texas Health Care System (US)
- Orlando Immunology Center (US)
- Community Services Institute (US)
- Jersey Shore University Medical Center (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1093/cid/ciaf597
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00